Login

Siu Wah Yau

ORCID: 0000-0002-2933-9978
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5079059472
Research Areas
  • Immune Cell Function and Interaction
  • Atherosclerosis and Cardiovascular Diseases
  • Cancer Immunotherapy and Biomarkers
  • Immune cells in cancer
  • T-cell and B-cell Immunology

University of Hong Kong
 2022

Chinese University of Hong Kong
 2022

 Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8+ T cell exhaustion and curtails anti-PD-1 efficacy
OPENALEX - Publications 
Weixin Chen Jia Ming Nickolas Teo Siu Wah Yau Melody Yee‐Man Wong Chun‐Nam Lok and 5 more Chi‐Ming Che Asif Javed Yuanhua Huang Stephanie Ma Guang Sheng Ling

Identifying signals that govern the differentiation of tumor-infiltrating CD8+ T cells (CD8+ TILs) toward exhaustion can improve current therapeutic approaches for cancer. Here, we show type I interferons (IFN-Is) act as environmental cues, enhancing terminal cell in tumors. We find enrichment IFN-I-stimulated genes (ISGs) within exhausted (Tex cells) patients across various cancer types, with heightened ISG levels correlating poor response to immune checkpoint blockade (ICB) therapy. In...

10.1016/j.celrep.2022.111647 article EN cc-by-nc-nd Cell Reports 2022-11-01
 Chronic Type I Interferons Signaling Promotes Lipid Peroxidation-Driven Terminal CD8 <sup>+</sup>T Cell Exhaustion and Curtails Anti-PD-1 Treatment Efficacy
OPENALEX - Publications 
Weixin Chen Jia Ming Nickolas Teo Siu Wah Yau Yee-Man Melody Wong Chun‐Nam Lok and 5 more Chi‐Ming Che Asif Javed Yuanhua Huang Stephanie Ma Guang Sheng Ling

Identifying signals that govern the differentiation of tumor-infiltrating CD8+T cells (CD8+TILs) towards exhaustion can improve current therapeutic approaches for cancer. Here, we show type I interferons (IFN-Is) act as environmental cues enhancing terminal cell in tumors. We found enrichment IFN-Is-stimulated genes (ISGs) within exhausted (Tex cells) patients across various cancer types, with heightened ISG levels correlatingwith poor response to immune checkpoint blockade (ICB) therapy. In...

10.2139/ssrn.4055642 article EN SSRN Electronic Journal 2022-01-01
Coming Soon ...